Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, NYU School of Medicine Form Precision Cancer Medicine Alliance

This article has been updated to add additional information about the terms of the alliance.

NEW YORK (GenomeWeb) – Tempus announced today that it has partnered with the New York University School of Medicine to generate and analyze genomic data from pancreatic cancer patients to help develop personalized treatments for the disease.

Under the terms of the deal, Tempus will structure and analyze data collected from around 500 pancreatic cancer patients by NYU Langone Health, and use next-generation sequencing assays to generate additional genomic data on a yet-to-be-determined subset of those patients. The work is expected to reveal genetic patterns that can be used to predict how patients will respond to particular therapies.

"Generating and analyzing the data may provide evidence for alternative treatment choices where patients have seen little benefit with the current standard of care," Tempus Founder and CEO Eric Lefkofsky said in a statement. "It is likely that a combined analysis of the genomic and phenotypic patterns of pancreatic cancer will lead to the next big breakthroughs in this difficult to treat cancer."

Tempus has formed personalized cancer medicine alliances with a number of research organizations recently including the Vanderbilt-Ingram Cancer Center, the Cleveland Clinic, and the University of California Davis Comprehensive Cancer Center.